KZA Media Thread, page-127

We already have good efficacy data with the most extremely sick and poor OS rate of patients one can imagine. Even the standard care to increase OS by just 9 months only works for one third of the patients. The bar of success in terms of OS is set very low for us and even the charity case of Josei Dunn has highlighted the drug is proving itself to at least one father and scientist it ture value. How does one value an extend life and especially that of a child?
and remember as a combination treatment value only increases as it is the case now with radiotherapy being tried